← Leaderboards
Lisa J McKerracher
Bioaxone Biosciences, Inc.
$3,392,953
Attributed
$6,067,014
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2014–18$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,067,014 · 6
By mechanism
R44$5,082,607 · 2
R43$984,407 · 4
Top collaborators
- Issam A Awad3 shared
- Douglas A Marchuk3 shared
- Rebecca A Stockton3 shared
- Alexey Wolfson2 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseSafetyPharmaceutical PreparationsToxic EffectRattusResponseImmunocytochemistryRecoveryIn VivoSignal TransductionMediatingResearch StudyAxon RegenerationPublic Health RelevanceNeuronsIn VitroLeadSafety StudySpinal Cord InjuryHistologyRoutePre-ClinicalAnimalsPrevent
Grant awards (10)
Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury$1,059,073
R44 · FY2018 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$1,576,432
R44 · FY2017 · NS · contact PI
Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury$735,822
R44 · FY2017 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$1,430,655
R44 · FY2016 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$280,625
R44 · FY2016 · NS · contact PI
Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury$319,201
R43 · FY2015 · NS · contact PI
Development of self-delivering RNAi to evaluate PTEN as a therapeutic target to p$224,789
R43 · FY2014 · NS · contact PI
Investigation of PEGylated BA-210 for RGC neuroprotection$223,651
R43 · FY2014 · EY · contact PI
Self-delivering RNAi to promote axon regeneration$191,766
R43 · FY2014 · NS
Regulatory development of PEGylated BA-210 for RGC neuroprotection$25,000
R43 · FY2014 · EY · contact PI